Search Results 1401-1410 of 21051 for magnesiummagnesium

  1. A Study to Evaluate the Safety and Effectiveness of Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness of NBI-74788 (100 mg twice daily [bid]), compared with placebo, in reducing daily glucocorticoid ...

  2. Moxidectin (oral route) - Mayo Clinic

    For the treatment of onchocerciasis: Adults and children 12 years of age and older—8 milligrams (mg) (four 2 mg tablets) as a single dose. Children ...

  3. Didanosine (oral route) - Mayo Clinic

    For patients weighing 20 kg to less than 25 kg—200 mg once a day. Children weighing less than 20 kg—The oral capsules are not given to small children. For oral ...

  4. Headache medicine ergot-derivative-containing (oral route, parenteral route, rectal route) - Mayo Clinic

    For dihydroergotamine. For relieving a migraine or cluster headache: Adults—1 mg. If your headache is not better, and no side effects are ...

  5. Modafinil (oral route) - Mayo Clinic

    For narcolepsy or obstructive sleep apnea/hypopnea syndrome: Adults and teenagers 17 years of age and older—200 milligrams (mg) once a day, in the morning. Your ...

  6. Thioxanthene (oral route, parenteral route) - Mayo Clinic

    For treatment of psychosis: For oral dosage forms (suspension or tablets):. Adults and teenagers—25 to 50 milligrams (mg) three or four times a day ...

  7. Xanomeline and trospium (oral route) - Mayo Clinic

    For oral dosage forms (capsules):. For treatment of schizophrenia: Adults—At first, 50 milligrams (mg) xanomeline and 20 mg trospium 2 times a day for at ...

  8. Lorlatinib (oral route) - Mayo Clinic

    For non-small cell lung cancer: Adults—100 milligrams (mg) once a day. Your doctor may adjust your dose as needed and tolerated. Children—Use and dose ...

  9. ORAL AZ-3102 in Patients With GM2 Gangliosidosis or Niemann Pick Type C Disease - Mayo Clinic

    ... mg and 9 mg AZ-3102 versus placebo when administered daily over 12 weeks in patients, and to investigate the plasma pharmacokinetic (PK) characteristics of 3 mg ...

  10. A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease - Mayo Clinic

    ... mg/dL of each other, with the most recent value within 14 days prior to the scheduled CT examination and the preceding value within 1 to 12 months before that).